苏州爱美津制药有限公司片剂生产扩建项目竣工及调试日期公示

新闻资讯 News

2018年8月10日

及时发布，请联系：
美国: (732) 993-9821
中国: +86-512-6745-1085 分机 101
info@amerigenpharma.com

根据《国务院关于修改〈建设项目竣工环境保护管理条例〉的决定》(国务院令第682号)，以及环保部《关于发布（建设项目竣工环境保护验收暂行办法）的公告》（国环规环评[2017]4号），现将苏州爱美津制药有限公司片剂生产扩建项目竣工情况公示如下：

项目名称：苏州爱美津制药有限公司片剂生产扩建项目

建设单位：苏州爱美津制药有限公司

建设地址：苏州工业园区群星一路58号

建设内容：公司拟投资1000万元，在现有生产车间内扩建片剂生产项目，项目建成后具备年增产片剂3.8亿片。

竣工时间：2018年8月10日。

调试日期：2018年8月11日-2018年8月12日。

公示期间，对上述公示内容如有异议，请以电话方式反馈。

联系人：季健华

联系方式：67451085-154

2018年8月10日

 

In accordance with the requirement of the State Council decision on amending “The Environmental Protection Regulations for the completion of construction projects” (Decree No. 682 of the State Council) and the announcement of the Ministry of Environmental Protection on the issue of “Interim Measures Of the Environmental Protection Acceptance For The Completion Of Construction Projects” (National Environmental Rules EIA [2017] No.4), the completion of the expansion project of Suzhou Amerigen Pharmaceutical Co., Ltd. is published as follows:

Project Name: Suzhou Amerigen Pharmaceutical Co., Ltd. Tablets Production Expansion

Construction Unit: Suzhou Amerigen Pharmaceutical Co., Ltd.

Construction Address: No.58, Qun Xing Yi Road, Suzhou Industrial Park

Construction Content: the company plans to invest 10 million RMB to expand the tablet production in the existing production workshop, and the production capacity will be increased of 380 million tablets per year after the project completion.

Completion Date: August 10, 2018

Commissioning Date: August 11, 2018 - August 12, 2018

If you have any objections during the publicity period, please contact Mr. Jianhua Ji via 67451085 (Ext. 154)

August 10, 2018

关于爱美津 About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

爱美津制药致力于仿制药所涉及到的全部阶段的业务，是一家包括美国和中国多成员企业的集团公司。集团由爱美津制药控股。美国市场的注册和商业活动由位于新泽西州，林赫斯特的美国爱美津负责；集团的中国分公司，苏州爱美津制药有限公司，位于中国江苏省苏州市。爱美津制药集团目前在美国以及中国均有药品上市和销售，同时，我们拥有活跃的在研产品组，面向美国食品药品监督管理局（FDA）注册和已申报若干个仿制药品种（ANDA），并且计划开展向中国食品药品监督管理局（CFDA）注册和申报产品的工作。爱美津从事开发的口服制剂产品，是开发难度高，需要专门的技术，或生产要求高度严格管理控制，以及法规复杂，需要规避或挑战专利的仿制药。爱美津集团旗下公司或合作方开发和生产的所有产品，都满足高质量标准，包括美国FDA。